Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Immunic Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Coya Therapeutics, Inc. (COYA), Nurix Therapeutics (...

Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (COYA), Nurix Therapeutics (NRIX) and Immunic (IMUX)

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Immunic yesterday and set a price target of $25.00. According to TipRanks, Matteis ...

Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)

Immunic ( ($IMUX) ) has issued an announcement. On May 28, 2026, Immunic, Inc. reported new data from its phase 2 CALLIPER trial of lead asset vido...

Immunic Highlights Positive Phase 2 CALLIPER MS Data

Immunic ( ($IMUX) ) just unveiled an update. Immunic, Inc., a Nasdaq-listed late-stage biotechnology company focused on novel oral therapies for ne...

Immunic Appoints New CEO to Lead MS Strategy

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avalo Therapeutics (AVTX) and Immunic (IMUX) with bu...

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Immunic (IMUX)

In a report released yesterday, Sam Slutsky from LifeSci Capital maintained a Buy rating on Immunic, with a price target of $56.00. Slutsky covers ...

Immunic (IMUX) Gets a Buy from LifeSci Capital

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunic (IMUX) and Tenon Medical, Inc. (TNON) with b...

Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Tenon Medical, Inc. (TNON)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara...

Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunic (IMUX) and Medline (MDLN) with bullish senti...

Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IMUX	$12.20	+1.12%	175.17K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IMUX	$12.20	+1.1%	175.17K
3
4
5
6

IMUX

IMUX

Dividend Overview

Get Immunic Inc. Data in Excel

Get Immunic Inc. Data in Excel